Genetic Marker Array for Diabetic Nephropathy Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and prediction of diabetic nephropathy in Chinese populations, with limited understanding of the interactive effects of genetic markers such as ACE, AGT, ALR2, and TNF-α polymorphisms on the development of this condition.
Innovation Solution
A method and array for detecting nephropathy in Chinese subjects using specific polymorphic sequences from the ACE, AGT, ALR2, and TNF-α genes, excluding ALR2 alone, to identify individuals at risk, involving genomic DNA extraction, PCR amplification, and sequencing to determine the presence of these markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic markers from multiple genes (ACE, AGT, ALR2, TNF-α) are used to predict diabetic nephropathy risk, then prediction accuracy is improved, but test complexity increases
Solution Approach 1:
The patent combines multiple genetic markers from different genes (ACE, AGT, ALR2, TNF-α) into a single integrated detection system. This merging approach allows simultaneous analysis of multiple polymorphisms to improve prediction accuracy for diabetic nephropathy risk, while managing the complexity through a unified testing platform rather than separate tests for each marker.
Solution Approach 2:
The detection system is designed to universally screen for multiple genetic markers associated with diabetic nephropathy across different populations. The array can detect various polymorphisms (I/D in ACE, M235T in AGT, CA repeats and C106T in ALR2, G-308A in TNF-α) using a single platform, making it a multi-functional tool that addresses multiple genetic risk factors simultaneously.
2Reliability
If early detection of nephropathy risk is implemented, then intervention effectiveness is improved, but detection cost increases
Solution Approach 1:
The patent implements preliminary detection of genetic markers before the actual development of diabetic nephropathy. By identifying individuals at high risk through genetic polymorphism analysis, early intervention strategies can be applied before renal damage occurs, improving intervention effectiveness. The detection includes screening for specific genotypes (ACE DD, AGT TT, ALR2 z-2/z-2 or CT/TT, TNF-α GG) that predispose individuals to nephropathy.
3Measurement precision
If population-specific genetic markers are used for Chinese diabetic patients, then diagnostic accuracy is improved, but applicability to other populations decreases
Solution Approach 1:
The patent applies local quality by tailoring the genetic marker panel specifically to Chinese diabetic populations. The detection system focuses on polymorphisms that have been shown to have significant associations with diabetic nephropathy in Chinese patients, such as the I/D polymorphism in ACE, M235T in AGT, CA repeats and C106T in ALR2, and G-308A in TNF-α. This localized approach maximizes diagnostic accuracy for the target population while acknowledging that different populations may require different marker panels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively identifies Chinese diabetic patients at risk for nephropathy, allowing for early intervention and targeted therapy, reducing the risk of renal complications and end-stage renal disease, with a 40-70% risk reduction demonstrated in clinical studies.
Implementation Method 1
PCR amplification, and sequencing to determine the presence of these markers
Data Source
AI summary
Disclosed is a method for detecting a Chinese diabetic subject suffering from, at risk for developing, or suspected of suffering from a nephropathy. The method includes determining whether a sample from the subject has at least one polymorphic sequence selected from the group consisting of polymorphic sequences an I/D genotype of an ACE gene, an M235T genotype of an AGT gene, a (CA) n-5′ (z-2) genotype of an ALR2 gene, an C106T genotype of an ALR2 gene in the promoter region, a G-308A genotype of a TNF-α gene, and a complement thereof, provided that the ALR2 gene cannot be used alone, in which the presence of the polymorphic sequence indicates the subject suffering from, or at risk for suffering from a nephropathy. Also provided is an array for detecting a Chinese diabetic subject suffering from, or at risk for suffering from a nephropathy.